Generic-drug makers challenge new Canadian patent rules
14th Nov 2006, 21:26 GMT
The generic pharmaceutical industry went to court Tuesday to challenge new federal regulations, which it says will block its ability to produce cheaper drugs and cost consumers millions of dollars.
Generic-drug makers challenge new Canadian patent rules related news:
- Generic drug makers launch suit against federal patent rules — The Globe and Mail - Health News
- Generic Drug Makers Launch Legal Challenge to New Federal Data Exclusivity Rules — ArriveNet : Government
- GSK reaches deal to end patent dispute — Latest news from Triangle Business Journal
- Teva Says Generic Zocor Decision Upheld — Financial News News from StratCenter.com
- Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex Injection Patent Litigation — Partnerships/ Joint Ventures News from StratCenter.com
- Spectrum Says It Reaches Glaxo Settlement — Pharmaceuticals News from StratCenter.com
- SpectraScience files new patent application — News-Medical News Feed
- Teva, Ranbaxy exclusivity on generic Zocor confirmed — HomePage
- U.S. delays Novartis diabetes drug — Marketplace by Bloomberg - International Herald Tribune
- Generex Biotechnology: First Metformin Gum Patent Granted to Generex Biotechnology — Market Wire - Pharmaceuticals and Biotech
Latest news from CBC | Health News:
- Fingerprinting dental patients raises privacy concerns
- Student confirmed with Norwalk
- Men who stay trim live longer, healthier lives
- Experts debate daily blood-sugar tests
- Drug Rituxan linked to bowel problems, Health Canada advises
- Air quality study to look at impact of oil industry
- Chocolate addicts offer sweet heart lesson
- 'Silent exodus' will greet rejection of pay demands: pharmacists
- Waiting mammograms getting read
- Face of lung disease in Canada increasingly female: report